ADAMTS2 and schizophrenia: This association was confirmed in two independent drug studies, where ADAMTS2 expression was reverted to “normal” levels in schizophrenia patients' peripheral blood mononuclear cells upon antipsychotic treatment targeting dopamine neurotransmission at the D1 and D2 receptors.131